Clinical trials: Normal Population
Warts
Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts
Hyperthermia treatment (hyperthermia) refers to treating diseases with temperature (39-45 ° C) beyond normal body temperature,. It has been reported that local warming at 44 ° C is able to effectively mobilize the body's immunity…
- Trial name
- NCT07534865
- Testing
- 3% hydrogen peroxide solution, 0.9 % saline, Hyperthermia at 44℃
- Where
- China
- Volunteers
- 210 people
- Sponsor
- First Hospital of China Medical University
Neuroblastoma, Sarcoma
Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]
To explore metabolic phenotypes of children with extra-cranial solid tumors and compare these with their histopathological and genetic alterations to discover potential novel biomarkers and therapeutic targets to improve outcomes…
- Conditions
- Neuroblastoma, Sarcoma, Pediatric Cancer
- Trial name
- NCT03686566
- Testing
- 13C-glucose, No glucose infusion
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Vitiligo
Investigating Healthcare Disparities in Vitiligo
Vitiligo is an acquired, non contagious skin disorder characterised by depigmented patches of skin that may appear in a localised or very generalised distribution, and affecting 0.5-2.0% of the global population.There are…
- Trial name
- NCT06097494
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 39,374 people
- Sponsor
- Momentum Data
Atopic Dermatitis
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
The purpose of this study is to evaluate the safety and efficacy of product 0405 in pediatric subjects with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT02176551
- Testing
- Product 0405
- Sponsor
- Fougera Pharmaceuticals Inc.
Acne Vulgaris
Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris
The primary objectives of the study is to show CD2475/101 40mg tablets taken once a day for 16 weeks is superior to the placebo in Change from baseline to Week 16(Last Observation Carry Forward, Intent To Treat) in inflammatory…
- Trial name
- NCT01320033
- Testing
- CD2475/101 40 mg, Doxycycline 100 mg
- Where
- 31 sites in United States
- Volunteers
- 662 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris
The objective of this study is to compare the safety and efficacy profiles of Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel…
- Trial name
- NCT01769235
- Testing
- Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, Acanya® Gel, 1.2%/2.5%, Vehicle of test product
- Volunteers
- 1,215 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris
This was a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations were performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12.
- Trial name
- NCT00422240
- Testing
- Adapalene/Benzoyl Peroxide, Adapalene Gel, 0.1%, Benzoyl Peroxide Gel 2.5%
- Where
- United States
- Volunteers
- 1,668 people
- Sponsor
- Galderma R&D
Onchocerciasis (River Blindness), Schistosomiasis
Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations
Neglected Tropical Diseases (NTDs) are among the most common groups of diseases affecting over one billion people globally and are disproportionately concentrated in remote, underserved, and marginalized communities.
- Conditions
- Onchocerciasis (River Blindness), Schistosomiasis, Soil Transmitted Helminth (STH) Infections, Lymphatic Filariasis
- Trial name
- MISSION (NCT07707817)
- Testing
- Modified Mass Administration of Medicines Strategy, Albendazole 400 mg, Praziquantel 40 mg/kg
- Where
- Nigeria
- Volunteers
- 5,760 people, healthy volunteers welcome
- Sponsor
- Uwemedimo Friday Ekpo
Streptococcus Group A
Incidence of Group A Strep Pharyngitis in School Children in Fiji
The purpose of this study is to find out how often group A Streptococcus (GAS) occurs in school-age children of Central Fiji. This bacterium often causes pharyngitis (sore throat) and can also cause pyoderma (skin infection) or…
- Trial name
- NCT00284882
- Where
- Fiji
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Streptococcus Group A
Streptococcal Infections in Fiji - Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji
Group A streptococcus (GAS) is a bacteria that causes many different sicknesses in children and adults. This study will look at the number of cases of pyoderma (bacterial skin infection) and scabies (skin mites that cause…
- Trial name
- NCT00436891
- Where
- Fiji
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in…
- Trial name
- NCT03911401
- Testing
- 0.3% OPA-15406, 1% OPA-15406
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Melanoma
cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project
Background: Metastatic melanoma has a devastating prognosis and is one of the top causes of cancer death in young patients. Until now, available therapies were few and unreliable, but recent understanding of melanomas' molecular…
- Trial name
- KitMel (NCT01543113)
- Testing
- sequencing
- Where
- 2 sites in France
- Volunteers
- 288 people
- Sponsor
- Rennes University Hospital
Bilateral Retinoblastoma, Childhood Intraocular Retinoblastoma
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
This phase II trial tests the safety and side effects of adding melphalan (by injecting it into the eye) to standard chemotherapy in early treatment of patients with retinoblastoma (RB).
- Conditions
- Bilateral Retinoblastoma, Childhood Intraocular Retinoblastoma, Group D Retinoblastoma, Stage I Retinoblastoma
- Trial name
- NCT05504291
- Testing
- Biospecimen Collection, Carboplatin, Etoposide
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Lupus Erythematosus, Systemic
A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.
- Trial name
- NCT03517722
- Testing
- Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg
- Where
- 204 sites in United States, Argentina and 18 more
- Volunteers
- 516 people
- Sponsor
- Janssen Research & Development, LLC
Epilepsy, Hippocampal Sclerosis
Gene Expression Changes of Brain Tissue in Human Temporal Lobe Epilepsy With Hippocampal Sclerosis
Epilepsy is a common neurological disease, manifested in the sudden abnormal discharge of neurons leading to short-term brain dysfunction, has become the neurology after headache the second most common disease.
- Trial name
- NCT04917939
- Testing
- RNA sequencing
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acne
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
The primary objective of this study is to compare the efficacy and safety and tolerability of ACYC Gel and vehicle in the treatment of subjects with Acne Vulgaris.
- Trial name
- ACYC (NCT01701024)
- Testing
- ACYC, ACYC vehicle
- Where
- 24 sites in United States
- Volunteers
- 498 people
- Sponsor
- Bausch Health Americas, Inc.
Systemic Lupus Erythematosus
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants…
- Trial name
- SIRIUS-SLE 1 (NCT05639114)
- Testing
- Ianalumab
- Where
- 135 sites in United States, Argentina and 17 more
- Volunteers
- 436 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren-Larsson Syndrome
RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects with Sjögren-Larsson Syndrome (SLS).
- Trial name
- NCT03445650
- Testing
- ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Acne Vulgaris
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12…
- Trial name
- NCT02073448
- Testing
- GK530G, CD0271, CD1579
- Where
- 13 sites in Japan
- Volunteers
- 417 people
- Sponsor
- Galderma R&D
Neutropenia, Sarcoma
Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor.
- Trial name
- NCT00002643
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 49 sites in United States, Australia and 3 more
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)